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Abstract 
Ex vivo studies have shown that the gastrin releasing peptide receptor (GRPr) is overexpressed on 
almost all primary prostate cancers, making it a promising target for prostate cancer imaging and 
targeted radiotherapy.  
Methods: Biodistribution, dosimetry and tumor uptake of the GRPr antagonist 
64Cu-CB-TE2A-AR06 
[(64Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG4-D-Phe-Gln-Trp-
Ala-Val-Gly-His-Sta-LeuNH2] were studied by PET/CT in four patients with newly diagnosed 
prostate cancer (T1c-T2b, Gleason 6-7).  
Results: No adverse events were observed after injection of 64Cu-CB-TE2A-AR06. Three of four 
tumors were visualized with high contrast [tumor-to-prostate ratio > 4 at 4 hours (h) post in-
jection (p.i.)], one small tumor (T1c, < 5% tumor on biopsy specimens) showed moderate contrast 
(tumor-to-prostate ratio at 4 h: 1.9). Radioactivity was cleared by the kidneys and only the pan-
creas demonstrated significant accumulation of radioactivity, which rapidly decreased over time.  
Conclusion: 64Cu-CB-TE2A-AR06 shows very favorable characteristics for imaging prostate 
cancer. Future studies evaluating 64Cu-CB-TE2A-AR06 PET/CT for prostate cancer detection, 
staging, active surveillance, and radiation treatment planning are necessary. 
Key words: Gastrin releasing peptide receptor, bombesin, PET/CT, prostate cancer. 
Introduction 
Treatment options for prostate cancer range 
from watchful waiting to aggressive multimodal 
therapies. In order to appropriately stratify patients to 
different treatment options, there is a need for imag-
ing techniques to accurately localize prostate cancer, 
determine the extent of disease, follow tumors over 
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time, and monitor their response to therapy. Routine 
imaging studies for prostate cancer include transrectal 
ultrasound, magnetic resonance imaging, x-ray com-
puted tomography and bone scintigraphy (1). Posi-
tron emission tomography (PET) with 11C- or 
18F-labeled choline has shown encouraging results for 
detection of recurrent prostate cancer (2), but has a 
low diagnostic accuracy for detection of primary 
prostate cancer, since prostatitis and benign prostatic 
hyperplasia also show increased choline uptake (3). 
An attractive target for a more sensitive and 
specific imaging of prostate cancer is the gastrin re-
leasing peptide receptor (GRPr), a member of the 
bombesin receptor family. GRPr and its ligand, gas-
trin releasing peptide (GRP), are physiologically ex-
pressed in the central nervous system and the gas-
trointestinal tract (4). GRPr overexpression has been 
observed in a variety of malignant tumors (4), but 
most consistently in prostate cancer. An autoradio-
graphic study found markedly increased binding of 
radiolabeled bombesin by prostatic intraepithelial 
neoplasia (PIN) and in all 30 primary prostate cancers 
studied. In contrast, normal and hyperplastic prostate 
tissue demonstrate no or very low binding of 
bombesin (5). 
Based on these data, several groups have studied 
radiolabeled GRPr agonists for imaging and radionu-
clide therapy of prostate cancer. However, most of 
these ligands demonstrated high gastrointestinal up-
take and limited metabolic stability in vivo. Further-
more, GRPr agonists can cause acute side effects (ab-
dominal cramps, emesis) when administered at high-
er doses, which are needed for radionuclide therapy 
(6). These limitations can potentially be overcome by 
radiolabeled GRPr antagonists. Non-radioactive la-
beled GRPr antagonists have been developed as an-
ti-cancer agents, since GRP is involved in mitogenic 
auto- and paracrine signaling loops (4). In clinical 
trials, these compounds were found to cause minimal 
side effects (7).  
Our group has developed several radiolabeled 
GRPr antagonists for imaging and radionuclide 
therapy of prostate cancer. In mice, these tracers 
showed higher tumor uptake than GRPr agonists. In 
addition, the antagonists showed rapid clearance 
from tissues with physiologic expression 
(gastrointestinal tract and pancreas), while they were 
retained for more than 24 h in GRPr expressing 
prostate tumor xenografts (8, 9). Of the studied GRPr 
antagonists, 64Cu-CB-TE2A-AR06 [(64Cu-4,11-bis(carb
oxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)
-PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-LeuNH2] 
(Figure 1) demonstrated the most favorable 
characteristics with respect to tumor uptake and 
tumor-to-organ ratios (8). The CB-TE2A chelator was 
chosen as it confers the highest stability for the 
64Cu-complex in vitro and in vivo (10). Compared to 
68Ga/64Cu-NODAGA-AR06, 64Cu-CB-TE2A-AR06 
showed superior pharmacokinetics with a distinctly 
higher tumor uptake (8). Imaging with 
64Cu-CB-TE2A-AR06 can be performed over several 
hours given the relatively long half-life of 64Cu (12.7 
h), which allows for better clearance of radioactivity 
from the urinary bladder. Furthermore, 64Cu-based 
radiopharmaceuticals can be produced centrally and 
shipped to hospitals without the ability to perform 
GMP compliant radiolabeling using short-lived 
radioisotopes such as 68Ga. Based on these 
considerations, we selected the 64Cu-CB-TE2A-AR06 
compound for initial clinical studies.  
Patients and Methods 
Patients 
Four patients with newly diagnosed, histologi-
cally proven (sextant core needle biopsy) prostate 
cancer without prior therapy underwent PET/CT 
imaging with 64Cu-CB-TE2A-AR06. Patient charac-
teristics are summarized in Table 1. Renal and hepatic 
function was normal in all patients as assessed by 
routine blood tests. 64Cu-CB-TE2A-AR06 PET/CT 
scanning was approved by the institutional review 
board and written informed consent was obtained 
from all patients. Patients were monitored for safety 
parameters from the time of administration until the 
end of the final PET/CT session via interview, elec-
trocardiography and measurements of heart rate and 
blood pressure. In addition, serum electrolytes, liver 
and pancreatic enzymes, creatinine levels and blood 
counts were measured before and 1-2 weeks after 
injection of 64Cu-CB-TE2A-AR06. 
 
Figure 1. Chemical structure of 64Cu-CB-TE2A-AR06. 
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Three patients underwent radiotherapy after the 
64Cu-CB-TE2A-AR06 PET/CT. Patient 4 underwent 
prostatectomy with local lymph node dissection. In 
this patient, a sample of the tumor was obtained and 
processed for in vitro receptor autoradiography with 
125I-Tyr4-bombesin as described previously (5).  
PET/CT imaging 
All imaging studies were performed at the Uni-
versity Hospital Freiburg and approved by the local 
IRB. Synthesis of the labeling precursor and subse-
quent 64Cu-labeling was carried out as described (8). 
Briefly, 20 µg of the peptide were dissolved in 0.1 
mol/L ammonium acetate buffer (pH 8.0) and incu-
bated with 64CuCl2 (220-350 MBq) at 95 °C for 15 
minutes (min). Quality controls were performed by 
analytic reversed-phase high performance liquid 
chromatography (RP-HPLC, Knauer) with a photo 
diode array detector (1200 series, Agilent Technolo-
gies) and a flow-through RamonaStar (Raytest 
GmbH) gamma-detector using a Macherey-Nagel 
Nucleosil 120 C18 column (eluents: A, 0.1% trifluoro-
acetic acid in water, and B, acetonitrile; gradient 1: 
0-30 min, 95%-30% A, and flow, 0.750 mL/min; gra-
dient 2: 0-3 min, 95%-50% A, and flow, 2.5 mL/min). 
The labeling yield was greater 99% and radiochemical 
purity greater 96%. For injection, the radioligand was 
diluted in 0.9% NaCl with 0.1% bovine serum albu-
min.  
All patients fasted for at least 4 hours before the 
administration of the radiopharmaceutical and were 
asked to void before starting the study. Patients un-
derwent a total of three PET scans starting 20 min, 4 h 
and 20 h p.i.. For logistical reasons, the first scan was 
performed with an ECAT EXACT 922 PET scanner 
(Siemens/CTI, Knoxville, TN) and the second and 
third scan with a 64-channel GEMINI TF PET/CT 
(Philips Healthcare, Cleveland, OH). Both scanners 
were cross-calibrated to ensure the comparability of 
the quantitative measurements. For attenuation cor-
rection of the PET images, one minute transmission 
scans were performed with three rotating germanium 
(68Ge) line sources (80-100 MBq each). At the time of 
the second scan, a contrast-enhanced diagnostic CT 
(120 kVp, 100-400 mAs, dose modulation) was per-
formed, and a low-dose CT (120 kVp, 25 mAs) was 
performed for attenuation correction at the last scan. 
One patient (patient 4) had a bladder catheter during 
the time of the PET/CT study because of 
long-standing urinary tract obstruction.  
Venous blood was sampled at 1, 2, 3, 4, 5, 10, 15, 
30 min, 1, 2, and 4 h p.i. and the amount of radioac-
tivity per mL blood was measured in a gamma coun-
ter (Perkin Elmer Packard, Cobra II). One milliliter of 
the 5 min, 30 min, 1 h and 4 h blood samples was 
centrifuged and 200 μL plasma was removed, treated 
with 400 μL ethanol and centrifuged to remove plas-
ma proteins. The supernatant was analyzed for me-
tabolites by RP-HPLC. In patients 2 and 3, urine was 
collected up to 18 h p.i.. Radioactivity concentration 
was measured for a 1 mL sample and total excreted 
activity was calculated. Due to logistical reasons, no 
urinary samples were obtained for patients 1 and 4. In 
patient 2, 10 mL of a urine sample obtained at 2 h was 
loaded on a C18 column and eluted with 1 mL of 
ethanol and analyzed by RP-HPLC.  
 
Table 1. Patient Characteristics. 1 Measured on TRUS. 
Patient Age Weight 
(kg)/ 
height (m) 
Result core needle biopsy: 
Gleason score, TNM classifica-
tion, tumor site and extension 
PSA 
(ng/mL) 
Prostate 
volume  
(mL) 1 
TRUS  
(Transrectal  
Ultrasound) 
DRE (Digital 
Rectal  
Examination) 
Therapy 
 
1 64 103/ 1.86 4/6 biopsies positive in left lobe 
[Gleason 6 (3+3), T1c], right lobe 
negative, tumor fraction 2% 
10.0 20 No abnormalities No  
abnormalities 
125I seed  
implantation 
2 77 100/ 1.83 3/4 biopsies positive in right 
lobe [Gleason 7 (4+3), T2a], left 
lobe negative, tumor fraction up 
to 40% 
4.6 40 Suspicious lesion 
in right prostatic 
lobe 
Enlargement of 
both prostatic 
lobes 
Percutaneous ra-
diotherapy and 
androgen depriva-
tion therapy 
3 70 78/ 1.78 Biopsies positive in right lobe 
[Gleason 7 (4+3), T2b], left lobe 
negative, tumor fraction 10% 
9.9 35 Suspicious lesion 
in right prostatic 
lobe 
Enlargement of 
right prostatic 
lobe with solid 
nodule 
Percutaneous ra-
diotherapy and 
interstitial  
after-loading 
4 73 71.5/ 1.70 Biopsies positive in both sides of 
the prostatic gland [Gleason 7 
(4+3), T2b], tumor fraction > 
90% in left lobe, 
< 1% in right lobe 
26.2 70 Considerable 
enlargement of 
both prostatic 
lobes, very inho-
mogeneous tex-
ture bilaterally 
Enlargement of 
both prostatic 
lobes, suspi-
cious solid nod-
ules bilaterally 
Prostatectomy and 
local lymph node 
dissection 
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Data analysis 
The uptake of 64Cu-CB-TE2A-AR06 was quanti-
fied by standardized uptake values (SUVs) normal-
ized to the patient’s body weight. Tumors were visu-
ally delineated in the slice with the highest tracer up-
take and the maximum SUVs were recorded. Because 
of the small tumor size, no SUVmean values were de-
termined because they would have been heavily in-
fluenced by partial volume effects. For normal organs, 
circular regions of interest were placed in the center of 
the organ to minimize partial volume effects. Results 
are presented as mean ± one standard deviation. Be-
cause of the small sample size, no further statistical 
analysis was performed. 
Using the image-derived time activity curves 
and the amount of activity excreted in the urine, ab-
sorbed doses were calculated with OLINDA/EXM 1.0 
using the dynamic bladder model with a 3-hour 
voiding interval (Vanderbilt University, Nashville, 
TN).  
Results 
The mean and standard deviation of the admin-
istered mass of 64Cu-CB-TE2A-AR06 was 14 ± 4 µg 
(range 10-17 µg). The mean administered activity was 
184 ± 51 MBq (range 130-233 MBq). There were no 
adverse or clinically detectable pharmacologic effects 
in any of the 4 subjects. No significant changes in vital 
signs or the results of laboratory studies or electro-
cardiograms were observed.  
In 3 out of 4 patients, the prostate tumor was 
visualized with high contrast on the 
64Cu-CB-TE2A-AR06 PET scans at all time points 
(Figure 2 and 3). In patient 1 (less than 5% tumor cells 
in the biopsy samples), modest focal uptake was ob-
served. The location of focal tracer uptake corre-
sponded well to the location of the tumor as deter-
mined by preoperative biopsies. In the patient who 
underwent surgery after the PET/CT scan, GRPr au-
toradiography confirmed the presence of GRP recep-
tors in the tumor tissue (Figure 3). 
64Cu-CB-TE2A-AR06 was rapidly cleared from the 
blood and excreted by the kidneys (Figure 4A). In 
patients 2 and 3, 80% and 70% of the injected activity 
were found in the urine within 18 h p.i.. Only the 
parent compound was detected in the 2 h urine sam-
ple. No metabolites were detected in the plasma at 5 
min p.i.. At the later time points, the activity concen-
tration in the plasma samples was below the thresh-
old for HPLC analysis. 
 
 
Figure 2. 64Cu-CB-TE2A-AR06 PET/CT study of patient 2. Images were acquired 4 h p.i.. A, B: Coronal sections of PET and fused PET/CT. C: Axial PET/CT 
fusion images at the levels indicated by dotted lines in A. There is intense uptake by the prostate tumor (red arrows) and the pancreas. Kidneys, liver and 
intestines show only low tracer uptake. The PET images are scaled to an SUV of 5 (color bar). 
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Figure 3. Correlation between in vivo PET and ex vivo autoradiography. A, B: Transaxial fused PET/CT and PET 4 h p.i.. C: Ex vivo GRP receptor 
autoradiography demonstrating GRPr expression by the tumor. 
 
Figure 4. A: Radioactivity concentration in the blood over time (mean and standard deviation) and bi-exponential fit of the data. The initial half-life of 
64Cu-CB-TE2A-AR06 is 5 minutes and the terminal half-life 165 minutes. B: Radioactivity concentration in the tumors over time. 
 
Radioactivity uptake above background was 
seen in kidneys, bladder, pancreas and intestine (Fig-
ures 2 and 3). At 4 h p.i., average SUVmean was 1.64 ± 
0.37 (kidney parenchyma), 5.86 ± 5.34 (urinary tract 
collection system), 14.03 ± 6.63 (bladder), and 6.73 ± 
3.34 (pancreas). Activity further cleared from these 
organs until the latest acquisition time point at 20 h 
p.i. [SUVmean 0.71 ± 0.34 (kidney parenchyma) and 0.28 
± 0.22 (pancreas)]. Liver, intestine and prostate 
showed low uptake at all-time points (SUVmean 1.8 ± 
1.02, 0.78 ± 0.68 and 0.95 ± 0.42 after 4 h). Washout of 
radioactivity was slower for tumors than for normal 
organs (Figure 4B), resulting in steadily increasing 
tumor-to-organ ratios over time (Figure 5). 
An effective radiation dose of 0.019 ± 0.008 
mSv/MBq was calculated. This resulted in an effec-
tive dose per study ranging from 2.47 to 4.49 mSv. The 
highest absorbed dose was found in the urinary 
bladder wall (0.176 ± 0.001 mSv/MBq) and the pan-
creas (0.094 ± 0.027 mSv/MBq). Individual organ 
doses are shown in Table 2 in comparison to literature 
data for 18F-fluorocholine (11). 
 
Figure 5. Tumor-to-normal-organ ratios over time. 
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Table 2. Radiation doses (mSv/MBq) after administration of 
64Cu-CB-TE2A-AR06 in comparison to literature data on 
18F-fluorocholine (11). 
Organ 64Cu-CB-TE2A-AR06 18F-fluorocholine 
Liver 0.039 ± 0.020 0.059 ± 0,012 
Spleen 0.031 ± 0.024 0.054 ± 0,021 
Pancreas 0.094 ± 0.027 not determined 
Kidney 0.033 ± 0.008 0.159 ± 0,072 
Urinary bladder wall 0.176 ± 0.001 0.063 ± 0,060 
Effective dose 0.019 ± 0.008 0.031 ± 0,007 
 
Discussion 
This pilot clinical study confirms the favorable 
biodistribution and high tumor uptake of GRPr an-
tagonists that have been observed in several preclini-
cal studies (8). The GRPr antagonist 
64Cu-CB-TE2A-AR06 rapidly cleared from organs 
with physiologic GRPr expression and was retained 
significantly longer in human prostate cancers. This 
resulted in steadily increasing tumor-to-background 
ratios over time. Due to the rapid renal clearance of 
64Cu-CB-TE2A-AR06, the calculated radiation expo-
sure for patients was comparable to a scan with the 
PET imaging probe 18F-fluorocholine (11).  
Several other probes are in clinical development 
for imaging of prostate cancer based on altered me-
tabolism, enzyme and receptor expression (12). The 
amino acid analogue anti-18F-FACBC (an-
ti-1-amino-3-18F-ﬂuorocyclobutane-1-carboxylic acid) 
is accumulated by prostate cancer cells via various 
amino acid transporters, especially the ASC (ala-
nine-serine-cysteine) transporter (12). An-
ti-18F-FACBC has shown encouraging results for im-
aging of primary prostate cancer, as well as lymph 
node metastases of prostate cancer (13). A recent pilot 
study has compared anti-18F-FACBC and 11C-choline 
in patients with biochemical recurrence of prostate 
cancer and found a higher detection rate with an-
ti-18F-FACBC than with 11C-choline (14).  
The enzyme prostate specific membrane antigen 
(PSMA, also known as folate hydrolase I and car-
boxypeptidase II) is expressed at the cell membrane of 
normal prostate cells, but is significantly up-regulated 
in prostate cancer (12). PSMA expression of prostate 
cancer has been targeted with antibodies and small 
molecule inhibitors of PSMA enzymatic activity (12). 
The radiolabeled antibody 111In-capromab has shown 
limited sensitivity for detection of prostate cancer, 
probably because it targets the intracellular portion of 
PSMA, which is not readily accessible by the antibody 
(12). Markedly higher uptake has been observed for 
the radiolabeled antibody J591, which targets the ex-
tracellular portion of PSMA. In pilot studies, high 
uptake of 89Zr-DFO-J591 was observed in primary 
prostate cancer (15), as well as in advanced castration 
resistant prostate cancer (16). While these data clearly 
indicate that PSMA is an interesting target for prostate 
cancer imaging, a disadvantage of 89Zr-DFO-J591 is its 
slow tumor uptake and slow blood clearance, which 
result in a high radiation exposure to the patient, and 
require imaging several days post injection. In con-
trast to antibody-based approaches for PSMA imag-
ing, radiolabeled small molecule PSMA inhibitors 
demonstrate a fast blood clearance and rapid tumor 
uptake. Imaging can be performed within one hour 
post injection. Both 18F- and 68Ga-labeled PSMA in-
hibitors have shown intense uptake in prostate cancer 
metastases (17, 18). A recent study has compared 
PET/CT with the 68Ga-labeled PSMA inhibitor 
Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] and 
18F-fluoromethylcholine PET/CT in 37 patients with 
metastatic prostate cancer. More metastatic lesions 
were detected with Glu-NH-CO-NH-Lys-(Ahx)- 
[68Ga(HBED-CC)] and lesion-to-background ratios 
were higher than for 18F-fluoromethylcholine (19).  
18F-ﬂuoro-5α-dihydrotestosterone (18F-FDHT) is 
a labeled androgen analog that evaluates androgen 
receptor expression in prostate cancer (20). However, 
serum testosterone needs to be at castration level for 
successful targeting of prostate cancer, which limits 
the usefulness of this tracer as a diagnostic agent (20). 
Future studies will be necessary to compare the 
ability of these different agents to image primary and 
metastatic prostate cancer. Because of the marked 
heterogeneity of prostate cancer at the time of diag-
nosis (21), and even more so at the time of recurrence 
(22), it is likely that several image probes will prove 
clinically useful for imaging various types and stages 
of prostate cancer. 
A large variety of bombesin receptor ligands 
have been tested preclinically (23-25), most of which 
were bombesin agonists. Among this large series of 
compounds, few were further evaluated in humans. 
An example is the 99mTc-labeled bombesin analogue 
99mTc-RP527, which was tested in patients with breast 
and prostate cancers (26). A frequent limitation of 
GRPr-targeting ligands has been their high uptake in 
the gastrointestinal tract, which may limit the detec-
tion of metastatic prostate cancer. Motivated by the 
superior imaging characteristics of somatostatin re-
ceptor antagonists (27), we (8, 9) and others (28) have 
studied GRPr antagonists in preclinical models of 
prostate cancer. In these studies, the antagonist 
demonstrated higher tumor uptake and lower gas-
trointestinal uptake than the agonists. Remarkably, 
normal tissues expressing GRPr, such as mouse or rat 
pancreas, consistently demonstrated much faster 
washout of the radioactivity than prostate cancers (8, 
9, 28).  
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In a very recent publication, a 68Ga-labeled GRPr 
antagonist (BAY86-7548, RM2) (29) was evaluated in 
patients with primary and recurrent prostate cancer. 
This radiotracer demonstrated focal uptake in pri-
mary prostate cancer, as well as lymph node metas-
tases. In one patient, bone metastases were false neg-
ative on BAY86-7548 PET/CT. Because of the short 
half-life of 68Ga, the kinetics of BAY86-7548 could only 
be studied over a period of approximately 2 h, 
whereas we studied tumor uptake and biodistribution 
of 64Cu-CB-TE2A-AR06 over a period of 20 h. Infor-
mation about the retention of GRPr antagonists is 
important for estimating patient dose and for poten-
tial therapeutic applications. Furthermore, the in-
creasing contrast between tumor and normal organs 
over time (Figure 5) suggests that delayed imaging 
may be beneficial for detection and staging of prostate 
cancer with GRPr antagonists. 
In our patient population, the kinetics of the 
GRPr antagonist 64Cu-CB-TE2A-AR06 were similar to 
preclinical studies. 64Cu-CB-TE2A-AR06 was rapidly 
accumulated by prostate cancer and cleared much 
slower from the tumors than from normal organs. The 
mechanisms for these differences between normal 
tissues and prostate cancer tissue are currently not 
known. However, our clinical data clearly indicate 
that this phenomenon is not limited to mouse models 
of prostate cancer, but occurs in a similar way in pa-
tients. 
The high tumor uptake of GRPr ligands make 
radionuclide therapy with GRPr ligands labeled with 
beta (30) or alpha (31) emitters feasible. The low in-
testinal and kidney uptake of GRPr antagonists, as 
well as the rapid washout of activity from the pan-
creas, observed in the present study and preclinically 
(8, 9), make these compounds particularly attractive 
for peptide receptor targeted radiotherapy (PRRT). 
Thus, imaging and therapeutic peptides could poten-
tially be used as theranostics for prostate cancer. 
Moreover, GRPrs have been demonstrated to be 
overexpressed in various other malignancies, such as 
small cell lung cancer, breast cancer and intratumoral 
blood vessels of ovarian malignancies (32, 33). Thus, 
PET/CT with 64Cu-CB-TE2A-AR06 may not only be 
used in prostate cancer, but also in several other 
prevalent malignant tumors. 
Conclusion 
These preliminary patient data are consistent 
with previous preclinical studies and suggest a fa-
vorable tumor uptake and image contrast of GRPr 
ligands for prostate cancer imaging. Studies in a con-
siderably larger number of patients will be necessary 
in order to determine the sensitivity of 
64Cu-CB-TE2A-AR06 PET/CT in relation to tumor 
size and other factors, such as Gleason scores. Nev-
ertheless, the encouraging preliminary data of this 
study indicate that further clinical evaluation of 
64Cu-CB-TE2A-AR06 and other GRPr antagonists is 
warranted. 
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